IDO1 and colitis: Mechanistically, priming with IFN-γ and TNF-α enhanced TSG-6 production through IDO-mediated tryptophan catabolism along the KYN pathway, thereby endowing MuSCs with more powerful therapeutic potency in DSS-induced colitis [7].